- Tarsus Pharmaceuticals (TARS, Financial) to release Q1 2025 financial results on May 1, 2025.
- A live webcast will be hosted at 1:30 p.m. PT / 4:30 p.m. ET.
- The webcast recording will be accessible for approximately 90 days.
Tarsus Pharmaceuticals, Inc. (TARS) has announced it will report its first quarter 2025 financial results on Thursday, May 1, 2025. Investors and interested participants can tune into the live webcast scheduled at 1:30 p.m. PT / 4:30 p.m. ET. This session will not only cover the financial results but also provide a corporate update.
Following the webcast, a recorded version will be made available on Tarsus' website, allowing viewers to access the information for up to 90 days post-event. This offers a significant opportunity for stakeholders to stay informed about the company's progress and future initiatives.
Tarsus Pharmaceuticals is known for its innovative approach in eye care, with products such as XDEMVY® (lotilaner ophthalmic solution) 0.25% already FDA-approved for treating Demodex blepharitis. The company is further expanding its pipeline, focusing on unmet medical needs across various therapeutic areas, including ocular rosacea and Lyme disease prevention.
